New Data Links GLP-1s to Poststroke Outcomes
MDSpire News
November 12, 2024
You now have access to the trusted editorial news and specialty content you've known from the Conexiant news site—all within the MDSpire experience.
Learn more

A study of 7,044 stroke survivors found lower cardiovascular event rates in patients treated with GLP-1 receptor agonists or SGLT2 inhibitors.
Patients receiving these medications had a 74% lower mortality risk and an 84% lower myocardial infarction risk compared to untreated patients.
SGLT2 inhibitor therapy was linked to a 67% lower risk of recurrent stroke in multivariate analysis.
The treatment group had a mortality rate of 11.8%, while the nontreatment group had a mortality rate of 54%.
The study's limitations included a predominantly White patient population and data sourced from a single health system.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
Stay up to date with the latest clinical headlines and other information tailored to your specialty.
Thank you for signing up for the Daily News alerts. You will begin receiving them shortly.
Affiliations:
Specialties:
Areas of Expertise: